Cargando…
Repeated Sigma-1 Receptor Antagonist MR309 Administration Modulates Central Neuropathic Pain Development After Spinal Cord Injury in Mice
Up to two-thirds of patients affected by spinal cord injury (SCI) develop central neuropathic pain (CNP), which has a high impact on their quality of life. Most of the patients are largely refractory to current treatments, and new pharmacological strategies are needed. Recently, it has been shown th...
Autores principales: | Castany, Sílvia, Codony, Xavier, Zamanillo, Daniel, Merlos, Manuel, Verdú, Enrique, Boadas-Vaello, Pere |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439356/ https://www.ncbi.nlm.nih.gov/pubmed/30967775 http://dx.doi.org/10.3389/fphar.2019.00222 |
Ejemplares similares
-
Critical role of sigma-1 receptors in central neuropathic pain-related behaviours after mild spinal cord injury in mice
por: Castany, Sílvia, et al.
Publicado: (2018) -
Long-Lasting Nociplastic Pain Modulation by Repeated Administration of Sigma-1 Receptor Antagonist BD1063 in Fibromyalgia-like Mouse Models
por: Álvarez-Pérez, Beltrán, et al.
Publicado: (2022) -
The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats
por: Gris, Georgia, et al.
Publicado: (2016) -
Central Neuropathic Pain Development Modulation Using Coffee Extract Major Polyphenolic Compounds in Spinal-Cord-Injured Female Mice
por: Soler-Martínez, Roger, et al.
Publicado: (2022) -
Epigallocatechin-3-gallate treatment to promote neuroprotection and functional recovery after nervous system injury
por: Boadas-Vaello, Pere, et al.
Publicado: (2015)